Phaseline

Companies › CytomX Therapeutics

CytomX Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Nov 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CX-2051
Probody therapeutic
–Phase 1Solid Tumor, AdultNov 2027
CX-801
Probody therapeutic (engineered antibody)
–Phase 1Solid Tumor, AdultFeb 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06265688CX-2051Phase 1Solid Tumor, AdultOncologyNov 2027
NCT06462794CX-801Phase 1Solid Tumor, AdultOncologyFeb 2028

From the company's SEC filings

Cash and short-term investments of $348m on 2026-09-30; operating cash outflow about $36m a year; runway about 115 months at that burn, to May 2036

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 6 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.